Ovarian Cancer Treatment Market Research Report, Share, and Forecast to 2025

Posted by rekha on October 14th, 2019

The global ovarian cancer treatment market was valued at US$ XX Mn in 2018 and increasing at a significant growth rate over the forecast years owing  to rising prevalence of ovarian cancer across the globe. According to the American Cancer Society, in 2018, there are about 22,240 cases of ovarian cancers diagnosed and 14,070 women die of ovarian cancer in the United States. Mortality rate for ovarian cancer have declined only slightly in the forty years since the “War on Cancer” was declared.  Moreover, increasing geriatric population coupled with use of combination therapies for the treatment of ovarian cancer expected to propel the global ovarian cancer treatment market over the forecast years. However, lack of awareness in the developing and underdeveloped economies and availability of generic drugs in the market and expiry of patents for the key drugs like taxol, gemzer, and paraplatin hampers the growth of ovarian cancer treatment market over the forecast timeframe

Global ovarian cancer treatment market segmented on the basis of type of cancer, drug class, distribution channel, and region

For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15743

Chemotherapeutic Agents Dominate the Global Ovarian Cancer Treatment Market

Based on the drug class, global ovarian cancer treatment market segmented into chemotherapeutic agents, targeted therapy drugs, immune system modulators, and hormones. Among all the drug classes, chemotherapeutic agents dominated the global ovarian cancer treatment market in 2018 and the same trend is expected over the forecast years owing to launch of newer products for the treatment of ovarian cancer into the market. For instance, in June 2019, Lynparza appoved in the EU for the 1st line maintenance treatment of BRAC-mutated advanced ovarian cancer. In June 2019, U.S. FDA accepts the GSK’s application for ZEJULA in late stage ovarian cancer with priority review.

North America Leads the Global Ovarian Cancer Treatment market

PBI’s global ovarian cancer treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to owing to increasing prevalence and incidence of ovarian cancer which is the most common cancer in United States and leading cancer for the death of women in the region. Presence of large number of market players focusing on research and developmental activities for the development of new drug for the ovarian cancer and number of products are being approved in recent days in the market. Asia Pacific is expected to show highest growth rate over the forecast period owing to increasing prevalence of ovarian cancer, however lack of awareness among the patients in the region is expected to restrain the growth of the market.

Strategic collaborations and approval for the reimbursement policies for the product are the key strategies adopted by market players

Global ovarian cancer treatment market further reveals that the key players increasingly adopting strategies such as strategic collaborations and approval for the reimbursement policies for the products to improve market revenue share and gaining significant geographic presence across the region. For instance. In December 2016 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation. In July 2019, NICE has approved the PARP inhibitor olaparib (Lynparza, AstraZeneca) for England’s cancer drugs fund (CDF)

Key player’s profiles in the report are Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia) , Aeterna Zentaris Inc. (U.S)., GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) ,

Precision Business Insights (PBI) in its report titled “Global Ovarian Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

Detailed Segmentation

By Type of Cancer

o    Epithelial Ovarian Tumor

o    Ovarian Germ Cell Tumor

o    Ovarian Stomatal Tumor

o    Primary Peritoneal Carcinoma

By Drug Class

o    Chemotherapeutic Agents

o    Targeted Therapy Drugs

o    Immune System Modulators

o    Hormones

By Distribution Channel

o    Hospital Pharmacies

o    Retail Pharmacies

o    Others


o     North America

  • U.S
  • Canada

o     Europe

  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe

o     Asia-Pacific

  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

o     Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

o     Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

For more information: https://www.precisionbusinessinsights.com/market-reports/global-ovarian-cancer-treatment-market/

Like it? Share it!


About the Author

Joined: July 26th, 2019
Articles Posted: 219

More by this author